Placeholder

LabCentral Houses Scientific Visionaries
Engaged in Early-Stage Research

Kronos Bio

Kronos Bio was founded in 2017 and is dedicated to the discovery and development of new therapies for cancer.  The company utilizes a novel approach to high-throughput screening of chemical libraries in order to identify binders or inhibitors of complex protein interactions, with a focus on modulating transcription factors and other challenging targets that have historically been considered ‘undruggable.’

Kronos Bio logo
Website - Coming Soon
  • Chris Wilfong Chief Operating Officer
  • Marius Pop, PhD Principal Scientist
  • David Freeman, PhD Senior Scientist